{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:35:47Z","timestamp":1784601347748,"version":"3.55.0"},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001325","name":"Cancer Association of South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Women's Dermatology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ijwd.2021.10.005","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T19:38:42Z","timestamp":1635190722000},"page":"625-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"PA","title":["Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management"],"prefix":"10.1097","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9255-8196","authenticated-orcid":false,"given":"Zoe","family":"Apalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"3","key":"10.1016\/j.ijwd.2021.10.005_bib0001","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.15340","article-title":"French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults","volume":"33","author":"Amatore","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.ijwd.2021.10.005_bib0002","doi-asserted-by":"crossref","first-page":"e14171","DOI":"10.1111\/dth.14171","article-title":"Alopecia areata as an immune-related adverse event of immune checkpoint inhibitors: A review","volume":"33","author":"Antoury","year":"2020","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.ijwd.2021.10.005_bib0003","doi-asserted-by":"crossref","first-page":"e14618","DOI":"10.1111\/dth.14618","article-title":"Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case","volume":"34","author":"Apalla","year":"2021","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.ijwd.2021.10.005_bib0004","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jaad.2020.05.045","article-title":"Management of immune checkpoint inhibitor-induced bullous pemphigoid","volume":"84","author":"Apalla","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2021.10.005_bib0005","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5826\/dpc.0904a11","article-title":"Psoriasis in patients with active lung cancer: Is apremilast a safe option?","volume":"9","author":"Apalla","year":"2019","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0006","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1007\/s00520-020-05701-9","article-title":"Immunotherapy-mediated dermatological adverse events: The urgent need for a common, clinically meaningful, management strategy","volume":"28","author":"Apalla","year":"2020","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.ijwd.2021.10.005_bib0007","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.annonc.2021.02.016","article-title":"IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies","volume":"32","author":"Barrios","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0008","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0009","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis: A study of 21 patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.ijwd.2021.10.005_bib0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jaad.2019.06.035","article-title":"Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events","volume":"82","author":"Chan","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2021.10.005_bib0011","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jaad.2019.09.026","article-title":"Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: A retrospective cohort study","volume":"82","author":"Chen","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.ijwd.2021.10.005_bib0012","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/cup.13312","article-title":"Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions","volume":"45","author":"Chen","year":"2018","journal-title":"J Cutan Pathol"},{"issue":"12","key":"10.1016\/j.ijwd.2021.10.005_bib0013","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1007\/s00520-020-05706-4","article-title":"Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors","volume":"28","author":"Choi","year":"2020","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.ijwd.2021.10.005_bib0014","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.ijwd.2021.10.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100251","article-title":"Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials","volume":"6","author":"Conforti","year":"2021","journal-title":"ESMO Open"},{"issue":"15","key":"10.1016\/j.ijwd.2021.10.005_bib0016","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1158\/1078-0432.CCR-21-0136","article-title":"Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion","volume":"27","author":"Conforti","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ijwd.2021.10.005_bib0017","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1007\/s00520-020-05709-1","volume":"28","author":"Cooksley","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune-checkpoint inhibitors: Review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ijwd.2021.10.005_bib0019","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/1078155216674355","article-title":"Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer","volume":"23","author":"Dasanu","year":"2017","journal-title":"J Oncol Pharm Pract"},{"issue":"10","key":"10.1016\/j.ijwd.2021.10.005_bib0020","doi-asserted-by":"crossref","first-page":"e684","DOI":"10.1111\/jdv.17388","article-title":"Morphea-like changes in the setting of cancer immunotherapy","volume":"35","author":"De Simone","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.ijwd.2021.10.005_bib0021","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: A descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.ijwd.2021.10.005_bib0022","doi-asserted-by":"crossref","first-page":"e13363","DOI":"10.1111\/dth.13363","article-title":"Severe de-novo palmoplantar and nail psoriasis complicating Nivolumab treatment for metastatic melanoma","volume":"33","author":"Di Altobrando","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0023","article-title":"Case reports of DRESS syndrome and symptoms consistent with DRESS syndrome following treatment with recently marketed monoclonal antibodies","volume":"2019","author":"Di Palma-Grisi","year":"2019","journal-title":"Autoimmune Dis"},{"issue":"12","key":"10.1016\/j.ijwd.2021.10.005_bib0024","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1007\/s00520-020-05707-3","article-title":"Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors","volume":"28","author":"Dougan","year":"2020","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.ijwd.2021.10.005_bib0025","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J Immunother"},{"issue":"11","key":"10.1016\/j.ijwd.2021.10.005_bib0026","doi-asserted-by":"crossref","first-page":"e1148","DOI":"10.1634\/theoncologist.2019-0094","article-title":"Sex differences in tolerability to anti-programmed cell death protein 1 therapy in patients with metastatic melanoma and non-small cell lung cancer: Are we all equal?","volume":"24","author":"Duma","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0027","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.ijwd.2021.10.005_bib0028","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0029","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.ijwd.2021.10.005_bib0030","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Flatz","year":"2019","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.ijwd.2021.10.005_bib0031","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamadermatol.2018.5071","article-title":"Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia","volume":"155","author":"Freites-Martinez","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.ijwd.2021.10.005_bib0032","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/jamadermatol.2017.0989","article-title":"Eruptive keratoacanthomas associated with pembrolizumab therapy","volume":"153","author":"Freites-Martinez","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0034","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2021.10.005_bib0035","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2019.08.045","article-title":"BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors","volume":"82","author":"Hasan Ali","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0036","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2019.05.018","article-title":"Generalised morphea induced by pembrolizumab","volume":"116","author":"Herrscher","year":"2019","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ijwd.2021.10.005_bib0037","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2021.10.005_bib0038","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/CMR.0000000000000518","article-title":"Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma","volume":"29","author":"Hwang","year":"2019","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0039","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2017.04.020","article-title":"Aprepitant for refractory nivolumab-induced pruritus","volume":"109","author":"Ito","year":"2017","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.ijwd.2021.10.005_bib0040","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/jnci\/djab035","article-title":"Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy","volume":"113","author":"Jing","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.ijwd.2021.10.005_bib0041","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1111\/jdv.17253","article-title":"Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1\/PD-L1 therapy: A national retrospective study","volume":"35","author":"Juzot","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.ijwd.2021.10.005_bib0042","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13293-020-00301-y","article-title":"The impact of sex and gender on immunotherapy outcomes","volume":"11","author":"Klein","year":"2020","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0043","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","article-title":"Ipilimumab in patients with cancer and the management of dermatologic adverse events","volume":"71","author":"Lacouture","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.ijwd.2021.10.005_bib0044","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"42","key":"10.1016\/j.ijwd.2021.10.005_bib0045","doi-asserted-by":"crossref","first-page":"e22555","DOI":"10.1097\/MD.0000000000022555","article-title":"The incidence risk of programmed cell death-1\/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis","volume":"99","author":"Li","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.ijwd.2021.10.005_bib0046","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0047","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1111\/ijd.14811","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: A systematic review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2021.10.005_bib0048","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/1346-8138.15345","article-title":"Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study","volume":"47","author":"Matsuya","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0049","first-page":"1","article-title":"Exclusive cutaneous and subcutaneous sarcoidal granulomatous inflammation due to immune checkpoint inhibitors: Report of two cases with unusual manifestations and review of the literature","volume":"2019","author":"Mobini","year":"2019","journal-title":"Case Rep Dermatol Med"},{"issue":"6","key":"10.1016\/j.ijwd.2021.10.005_bib0050","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/bjd.19313","article-title":"Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: A cross-sectional study","volume":"183","author":"Molina","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0051","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0052","article-title":"Reply to: \u201cComment on Bullous pemphigoid after anti-PD-1 therapy: a retrospective case-control study evaluating impact on tumor response and survival outcomes","author":"Nelson","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.ijwd.2021.10.005_bib0053","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaad.2020.08.137","article-title":"Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group","volume":"84","author":"Nikolaou","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2021.10.005_bib0054","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1634\/theoncologist.2019-0467","article-title":"Sicca syndrome induced by immune checkpoint inhibitor therapy: Optimal management still oending","volume":"25","author":"Ortiz Brugu\u00e9s","year":"2020","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ijwd.2021.10.005_bib0055","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/annonc\/mdx818","article-title":"Immune-related adverse events of immune checkpoint inhibitors and the impact of sex-what we know and what we need to learn","volume":"29","author":"\u00d6zdemir","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0056","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jamadermatol.2018.4560","article-title":"Clinical characterization of immunotherapy-related pruritus among patients seen in 2 oncodermatology clinics","volume":"155","author":"Phillips","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"30","key":"10.1016\/j.ijwd.2021.10.005_bib0057","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.ijwd.2021.10.005_bib0058","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint-blocking antibody side effects","author":"Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ B"},{"issue":"2","key":"10.1016\/j.ijwd.2021.10.005_bib0059","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0060","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2019.0046","article-title":"Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma","volume":"5","author":"Quach","year":"2019","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.ijwd.2021.10.005_bib0061","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1007\/s00520-020-05727-z","article-title":"MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors","volume":"28","author":"Rapoport","year":"2020","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.ijwd.2021.10.005_bib0062","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/CCO.0000000000000736","article-title":"Supportive care for new cancer therapies","volume":"33","author":"Rapoport","year":"2021","journal-title":"Curr Opin Oncol"},{"issue":"10","key":"10.1016\/j.ijwd.2021.10.005_bib0063","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s00520-017-3802-9","article-title":"Supportive care for patients undergoing immunotherapy","volume":"25","author":"Rapoport","year":"2017","journal-title":"Support Care Cancer"},{"issue":"11","key":"10.1016\/j.ijwd.2021.10.005_bib0064","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1634\/theoncologist.2019-0250","article-title":"Serious cutaneous toxicities with immune checkpoint inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System","volume":"24","author":"Raschi","year":"2019","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.ijwd.2021.10.005_bib0065","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamadermatol.2017.2106","article-title":"Hair repigmentation during immunotherapy treatment with an anti\u2013programmed cell death 1 and anti\u2013programmed cell death ligand 1 agent for lung cancer","volume":"153","author":"Rivera","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.ijwd.2021.10.005_bib0066","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/ijd.15163","article-title":"Dermatological side effects rarely interfere with the continuation of checkpoint inhibitor immunotherapy for cancer","volume":"59","author":"Rovers","year":"2020","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2021.10.005_bib0067","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000478898","article-title":"Recurrence of melanoma after starting apremilast for psoriasis","volume":"9","author":"Salopek","year":"2017","journal-title":"Case Rep Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2021.10.005_bib0068","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cup.12666","article-title":"Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy","volume":"43","author":"Schaberg","year":"2016","journal-title":"J Cutan Pathol"},{"issue":"5","key":"10.1016\/j.ijwd.2021.10.005_bib0069","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jaad.2020.05.133","article-title":"Management of oral reactions from immune checkpoint inhibitor therapy: A systematic review","volume":"83","author":"Shah","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.ijwd.2021.10.005_bib0070","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1007\/s00520-020-05708-2","article-title":"Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: Pulmonary toxicity","volume":"28","author":"Shannon","year":"2020","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.ijwd.2021.10.005_bib0071","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/odi.13218","article-title":"Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series","volume":"26","author":"Shazib","year":"2020","journal-title":"Oral Dis"},{"issue":"10","key":"10.1016\/j.ijwd.2021.10.005_bib0072","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0073","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0074","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1111\/jdv.14284","article-title":"Oral lichenoid reactions associated with anti-PD-1\/PD-L1 therapies: Clinicopathological findings","volume":"31","author":"Sibaud","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0075","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2019.08.030","article-title":"Pages-Laurent C. Nivolumab-related mucous membrane pemphigoid","volume":"121","author":"Sibaud","year":"2019","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ijwd.2021.10.005_bib0076","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti\u2013PD-1 and anti\u2013PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0077","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jaad.2017.04.1142","article-title":"Alopecia areata: An appraisal of new treatment approaches and overview of current therapies","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.ijwd.2021.10.005_bib0078","doi-asserted-by":"crossref","first-page":"6159","DOI":"10.1007\/s00520-020-05710-8","article-title":"Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors","volume":"28","author":"Suarez-Almazor","year":"2020","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.ijwd.2021.10.005_bib0079","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/bjd.20074","article-title":"Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity","volume":"185","author":"Thompson","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0080","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.ejim.2018.07.023","article-title":"Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series","volume":"57","author":"Tomelleri","year":"2018","journal-title":"Eur J Int Med"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0081","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jdcr.2021.02.016","article-title":"Anti-PD-1-induced lichenoid changes of the nail unit: Histopathologic description","volume":"10","author":"van Damme","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.ijwd.2021.10.005_bib0082","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00520-017-3629-4","article-title":"Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors","volume":"25","author":"Vigarios","year":"2017","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.ijwd.2021.10.005_bib0083","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.currproblcancer.2017.10.003","article-title":"Anti-PD1\/PDL1 induced psoriasis","volume":"41","author":"Voudouri","year":"2017","journal-title":"Curr Probl Cancer"},{"issue":"9","key":"10.1016\/j.ijwd.2021.10.005_bib0084","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","article-title":"Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy","volume":"154","author":"Wang","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.ijwd.2021.10.005_bib0085","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.ijwd.2021.10.005_bib0086","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ijwd.2021.10.005_bib0087","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/cncr.33436","article-title":"Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019","volume":"127","author":"Xu","year":"2021","journal-title":"Cancer"}],"container-title":["International Journal of Women's Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352647521001271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352647521001271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T14:28:26Z","timestamp":1641565706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352647521001271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":86,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2352647521001271"],"URL":"https:\/\/doi.org\/10.1016\/j.ijwd.2021.10.005","relation":{},"ISSN":["2352-6475"],"issn-type":[{"value":"2352-6475","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management","name":"articletitle","label":"Article Title"},{"value":"International Journal of Women's Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijwd.2021.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc. on behalf of Women's Dermatologic Society.","name":"copyright","label":"Copyright"}]}}